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Oestradiol Contributes to Differential
Antitumour Effects of Adjuvant
Zoledronic Acid Observed Between
Pre- and Post-Menopausal Women
Victor G. Canuas-Landero, Christopher N. George, Diane V. Lefley, Hannah Corness,
Munitta Muthana, Caroline Wilson and Penelope D. Ottewell*
Department of Oncology and Metabolism, The Mellanby Centre for Musculoskeletal Research, The University of Sheffield,
Sheffield, United Kingdom
Clinical trials have demonstrated that adding zoledronic acid (Zol) to (neo)adjuvant
standard of care has differential antitumour effects in pre- and post-menopausal
women: Both benefit from reduced recurrence in bone; however, whi le
postmenopausal women also incur survival benefit, none is seen in premenopausal
women treated with adjuvant bisphosphonates. In the current study, we have used
mouse models to investigate the role of oestradiol in modulating potential antitumour
effects of Zol. Pre-, peri-, and post-menopausal concentrations of oestradiol were
modelled in BALB/c wild-type, BALB/c nude, and C57BL/6 mice by ovariectomy
followed by supplementation with oestradiol. Mice also received 40 mg/kg/day
goserelin to prevent ovariectomy-induced increases in follicle-stimulating hormone
(FSH). Metastasis was modelled following injection of MDA-MB-231, 4T1, or E0771
cells after ovariectomy and saline or 100 mg/kg Zol administered weekly. Supplementing
ovariectomised mice with 12.5 mg/ml, 1.38 mg/ml, and 0 ng/ml oestradiol, in the
presence of goserelin, resulted in serum concentrations of 153.16 ± 18.10 pg/ml,
48.64 ± 18.44 pg/ml, and 1.00 ± 0.27 pg/ml oestradiol, which are equivalent to
concentrations found in pre-, peri-, and post-menopausal humans. Osteoclast activity
was increased 1.5–1.8-fold with peri- and post-menopausal compared with
premenopausal oestradiol, resulting in a 1.34–1.69-fold reduction in trabecular bone.
Zol increased trabecular bone in all groups but did not restore bone to volumes observed
under premenopausal conditions. In tumour-bearing mice, Zol reduced bone metastases
in BALB/c (wild-type and nude), with greatest effects seen under pre- and post-
menopausal concentrations of oestradiol. Zol did not affect soft tissue metastases in
immunocompetent BALB/c mice but increased metastases 3.95-fold in C57BL/6 mice
under premenopausal concentrations of oestradiol. In contrast, Zol significantly reduced
soft tissue metastases 2.07 and 4.69-fold in immunocompetent BALB/c and C57BL/6
mice under postmenopausal oestradiol, mirroring the results of the clinical trials of (neo)
adjuvant bisphosphonates. No effects on soft tissue metastases were observed in
immunocompromised mice, and differences in antitumour response did not correlate
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with musculoaponeurotic fibrosarcoma (MAF), macrophage capping protein (CAPG), or
PDZ domain containing protein GIPC1 (GIPC1) expression. In conclusion, oestradiol
contributes to altered antitumour effects of Zol observed between pre- and post-
menopausal women. However, other immunological/microenvironmental factors are
also likely to contribute to this phenomenon.
Keywords: breast cancer, zoledronic acid, oestradiol, menopause, bone microenvironment
INTRODUCTION
Bone is the predominant site for breast cancer metastases (1),
and relapse most frequently occurs decades after the primary
tumour has been removed. It is therefore presumed that
disseminated tumour cells (DTCs) stay in a dormant state,
possibly within the bone, for many years (2). The bone
marrow microenvironment can influence these tumour cells to
remain dormant, reactivate to form overt metastases or to be
shed back into the bloodstream from which they can seed other
organs (2, 3). Importantly, the bone microenvironment can be
altered by both the bone-targeting bisphosphonates (4–6) and
reproduct ive hormones such as oes t rad io l (7–9) .
Bisphosphonates, such as zoledronic acid (Zol), can affect cells
within the bone microenvironment and influence the ability of
tumour cells to establish in bone as metastases. In clinical studies,
Zol decreased the number of DTCs in bone marrow aspirates
from breast cancer patients (10–12), suggesting the DTCs had
been killed, moved to another site in the body, or had entered a
state of dormancy. Oestradiol has differential effects on the bone
environment to Zol, actively promoting osteoblast-mediated
bone formation (13). This, in addition to multiple additional
effects on the vasculature, immune cells, bone marrow
progenitors, haematopoetic stem cells, and cancer-associated
fibroblasts [reviewed in (14, 15)], may be a mechanism by
which oestradiol inhibits antitumour effects of Zol in
premenopausal patients.
The preclinical and clinical evaluation of the antitumour
effects of Zol commenced over a decade ago, but the first
suggestion of interplay between Zol, menopausal status, and
breast cancer recurrence only emerged in 2011 when reported by
the ABCSG-12 and AZURE studies (16, 17). The AZURE study,
which randomized 3,360 patients to receive 4 mg Zol for 5 years,
showed a reduction in breast cancer recurrence with Zol in
women who were >5 years postmenopausal (17). More recently,
the 10-year follow-up data have shown a persistent increase in
disease-free survival events outside of bone in women <40 years
of age receiving Zol (18), suggesting that, in younger women with
high levels of reproductive hormones, Zol may displace tumour
cells out of the bone to distant sites. A meta-analysis of individual
patient data from 18,766 women treated in breast cancer clinical
trials with adjuvant bisphosphonates confirmed that
postmenopausal women (defined clinically) had reduced
recurrence rates at all distant sites (RR 0.82, 0.74–0.92; 2p =
0.0003), in bone specifically (0·72, 0·60–0·86; 2p = 0·0002), and
improved overall breast cancer mortality (0.82, 0.73–0.93; 2p =
0.002) (19), but the increase in distant non-bone recurrence in
premenopausal women treated with bisphosphonates was not
demonstrated as it has been in the AZURE trial.
There is emerging evidence that oestradiol is a key hormone
that can influence sites of breast cancer metastases. As part of the
AZURE trial, a large number of baseline serum samples were
collected and evaluated for baseline hormone levels [oestradiol,
follicle-stimulating hormone (FSH), and inhibin]. These data
showed an association between oestradiol levels of <50 pmol/l
(postmenopausal range) and a significantly shorter invasive
disease-free survival compared to an oestradiol level of ≥50
pmol/l [hazard ratio (HR) = 1.36; 95% CI 1.05–1.78; p =
0.022] (20). This was driven by more distant recurrences
(outside of bone), regardless whether the primacy tumour was
oestradiol receptor-positive (ER+ve) or -negative (ER-ve),
indicating that very low levels of oestradiol may make the bone
less attractive to DTCs, and therefore, they seek sites outside of
bone in which to establish as metastatic disease. In support of
this, in vivo studies have shown that supplementing mice with a
17b-oestradiol pellet enhanced spontaneous metastasis of ER+ve
cells to bone (13), suggesting that high oestradiol may attract
tumour cells to bone and may influence whether they survive/
become dormant cells in the bone microenvironment or
disseminate to other organs.
The current study aimed to identify the mechanisms by which
oestradiol and Zol may interact to affect the bone
microenvironment and tumour growth in bone and non-bone
sites. To achieve this, we modelled physiologically relevant levels
of oestradiol: 1) very low levels seen in aromatase inhibitor use in
postmenopausal women; 2) low levels that we would expect in
perimenopausal women; and 3) higher levels that we would find
in premenopausal women in mice in the absence of tumour cells
or before tumour cell dissemination into the circulation ± Zol.
MATERIALS AND METHODS
Cell Culture
Cell lines used were as follows: human triple-negative MDA-MB-
231 breast cancer cells (European Collection of Authenticated
Cell Cultures, Wiltshire, UK) transfected with green fluorescent
protein (GFP) and Luc2 (21) and triple-negative mouse
mammary 4T1 and E0771 cells (kindly donated by Dr. Amy
Kwan, University of Sheffield, Sheffield, UK, and Dr. Sandra
McAllister, Harvard Medical School, USA, respectively)
transfected with Luc2 (22, 23). MDA-MB-231 and 4T1 cell
lines were maintained in Dulbecco’s modified Eagle’s medium
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(DMEM, Gibco, UK) supplemented with 10% fetal bovine serum
(FBS; Gibco, UK), whereas E0771 cells were maintained in RPMI
(Gibco, UK) supplemented with 10% FBS. MDA-MB-231-GFP-
Luc2 was used within 30 passages, and 4T1-Luc2 and E0771-
Luc2 were used within 20 passages after receipt.
Generating Bone Metastatic 4T1 Cells
Here, 5 × 104 4T1-Luc2 cells were grown in DMEM + 10% FBS,
washed, and prepared for intracardiac (i.c.) injection into 12-
week-old female BALB/c mice (n = 5) (Charles River, UK).
Tumour growth was monitored by an IVIS Lumina II system
(Calliper Life Sciences, UK). Animals were sacrificed 2 weeks
after injection of tumour cells. All tumour-bearing bones were
isolated in a sterile environment and dissociated aseptically to
collect 4T1-luc cells using Miltenyi tumour cell dissociation kit
(Miltenyi Biotech, Germany). Selection of 4T1-luc cells was
carried out using 60 mmol/L 6-thioguanine. Cultured colonies
were grown and used for further in vivo experiments.
In Vivo Studies
Experiments used 12-week-old female BALB/c wild-type,
BALB/c fox/- nude, and C57BL/6 mice (Charles River, Kent,
UK) kept on a 12-h/12-h light/dark cycle with free access to
food and water. All studies were carried out in accordance with
local guidelines and with Home Office approval under project
licences 70/8964 and P99922A2E, University of Sheffield, UK.
Modelling of human pre-, peri-, and post-menopausal
concentrations of oestradiol only was established by
ovariectomising (OVX) mice to negate effects of other ovarian
hormones, i.e., inhibin [as previously described (24, 25)] prior to
supplementation with 17b-oestradiol (Sigma Aldrich, Poole, UK)
at 12.5, 1.38, or 0 mg/L via their drinking water. To prevent
predicted release of oestradiol from other tissues including adipose
tissue as well as increases in FSH, 40 µg/kg/day goserelin (as
goserelin acetate, Sigma Aldrich, UK) was administered via
subcutaneous injection. Success of OVX ± oestradiol
supplementation was assessed by imaging and weighing of
mouse uterus at the end of each procedure (Supplementary
Figure S1) and checking serum concentrations of oestradiol and
FSH by ELISA. For experiments designed to investigate the effects
of Zol on the bone microenvironment in the absence of tumours,
100 µg/kg Zol (supplied as disodium salt by Novartis) or
phosphate buffered saline (PBS; control) was administered once
per week starting 7 days after OVX (n = 5/group). Mice were
sacrificed 14 days after OVX, and serum was collected and stored
at -80°C for downstream analysis by ELISA, tibiae and femora
were fixed in 4% paraformaldehyde (PFA; Fisher Scientific, UK)
for mCT analysis before decalcification in 0.5 M EDTA and
processing for histology (Supplementary Figure S2A).
To investigate the effects of Zol on tumour distribution under
established pre-, post-, and peri-menopausal concentrations of
oestradiol, 1 × 105 MDA-MB-231-GFP-Luc2 cells were injected
into the left cardiac ventricle (i.c.) of BALB/cfox/- nude mice 3
days after OVX ± oestradiol + goserelin; or 5 × 104 4T1-Luc2
cells were injected i.c. into BALB/c mice 6 days following OVX ±
oestradiol + goserelin; or C57BL/6 mice were injected with 1 ×
105 E0771-Luc2 i.c. 7 days following OVX ± oestradiol +
goserelin. At 3 days after injection of tumour cells, 100 µg/kg/
week Zol or PBS (control) was injected subcutaneously (s.c.) to
the corresponding groups (n = 10/group) until the end of the
experiment. BALB/c fox/- nude, BALB/c, and C57BL/6 mice were
sacrificed 28, 15, and 19 days after OVX, respectively. Serum was
collected and stored at -80°C for downstream analysis by ELISA,
tibiae and femora were fixed in 4% PFA for mCT analysis before
decalcification in 0.5 M EDTA and processing for histology
(Supplementary Figures S2B, C).
In Vivo Tumour Measurement
Tumour growth was monitored, in live mice, using an IVIS
Lumina II system (Caliper Life Sciences, UK). Here, 30 mg/kg of
D-Luciferin (Invitrogen, UK) was injected s.c. 4 min before
imaging. Mice were imaged by dorsal and ventral exposure.
Hind limbs and internal organs were extracted for additional ex
vivo imaging after termination of the experiment. All images
were analysed by creating a region of interest (ROI) around the
tumour(s); luminescence signal was acquired in radiance
(photons/second).
Microcomputed Tomography Imaging
Microcomputed tomography (mCT) analysis was carried out on
fixed tibiae using a Skyscan 1172 x-ray–computed
microtomography scanner (Skyscan, Aartselaar, Belgium)
equipped with an x-ray tube (voltage, 49 kV; current, 200 mA)
and a 0.5-mm aluminium filter. Pixel size was set to 4.3 mm, and
scanning initiated from the top of the proximal tibia as
previously descried (26).
Bone Histology
Tibiae and femora were fixed in 4% PFA for a minimum of 48 h
prior to decalcification with 0.5 M EDTA at pH 7.0 for 3 weeks,
changing the solution at weekly intervals. Bones were embedded
in paraffin wax, and sections of 3 µm were taken using a
microtome. Osteoclast identification was carried out by
tartrate-resistant acid phosphatase (TRAcP) for consistency
staining. Osteoblasts were identified as mononuclear cuboidal
cells residing in chains along the bone surface. The number of
osteoclasts and osteoblasts was analysed per millimetre in the
cortical–endosteal bone and trabecular bone surfaces. Leica
RMRB upright microscope and OsteoMeasure software
(Osteometrics Inc.) were used for osteoclast and osteoblast
scoring (27).
Biochemical Analysis
Serum concentrations of Tartrate-Resistant Acid Phosphotase 5b
(TRAcP 5b), procollagen 1 intact N-terminal propeptide (P1NP),
oestradiol, and FSH were measured using commercially available
ELISA kits: MouseTRAP™Assay (Immunodiagnostic Systems), Rat/
Mouse P1NP competitive immunoassay kit (Immunodiagnostic
Systems), Mouse/Rat oestradiol ELISA (CALBIOTECH), and
Mouse FSH (Elabsciences) and standard protocols, respectively.
Gene Expression
Total RNA was extracted using an RNeasy kit (Qiagen) and
manufacturers’ instructions. For Affymetrix array analysis, RNA
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was amplified using LunaScript RT SuperMix Kit (New England
BioLabs, USA) before being reverse transcribed into cDNA using
Superscript III (Invitrogen AB). Gene expression was assessed by
analysing the number of cycles (CT) taken for expression of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; control)
musculoaponeurotic fibrosarcoma (MAF), macrophage capping
protein (CAPG), and PDZ domain containing protein GIPC1
(GIPC1) to be detected using the following assays: Hs00894322
for GAPDH, Hs01533575 forMAF, Hs 05867157 for CAPG, and
Hs Hs01149347 for GIPC1 in human MDA-MB-231 cells and
Mm00186822 for GAPDH, Mm0300214 forMAF, Mm00179028
for CAPG, and Mm00252127 for mouse 4T1 and E0771. All PCR
assays were performed using an ABI 7900 PCR System (Perkin
Elmer, Foster City, CA) and Taqman universal master mix (all
reagents were purchased from Applied Biosystems via
Thermofisher, UK).
Statistical Analysis
Statistical analysis was performed using Prism GraphPad
(version 8.0). Data are represented as mean ± SEM. Statistical
significance was measured using parametric testing, assuming
equal variance. Analysis was by one-way analysis of variance
(ANOVA) followed by Newman–Keuls multiple comparison
test, and standard unpaired t-tests were used to assess the
difference between test and control samples. Statistical
significance was defined as p ≤ 0.05. All graphs represent
mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
RESULTS
Effects of Oestradiol and Zoledronic Acid
on the Bone Microenvironment
Our hypothesis is that oestradiol-induced changes to the bone
microenvironment affect metastatic outgrowth in bone and soft
tissue. As female mice have low circulating concentrations of
oestradiol compared with humans [65.94 ± 25.28 pg/ml in 14-
week-old mice (Supplementary Figure S3) compared with 40–400
in premenopausal women] and do not naturally undergo
menopause, we used OVX to establish low baseline
concentrations of oestradiol and inhibin. This procedure did not
reduce oestradiol release from other endocrine organs; therefore,
mice also received 40 mg/kg/day goserelin to further reduce
circulating concentrations of oestradiol to 1.01 ± 0.27 pg/ml
(Supplementary Figure S3) and prevent OVX-induced release
of FSH (Supplementary Figure S4). Mice were subsequently
supplemented with 17b-oestradiol in their drinking water to
establish concentrations of this hormone that are representative
of pre-, post-, and peri-menopausal concentrations observed in
women. Supplementation with 12.5, 1.38, or 0 mg/L resulted in
serum concentrations of 153.16 ± 18.10, 48.64 ± 18.44, and 1.00 ±
0.27 pg/ml, respectively (Figure 1A). These concentrations are
comparable to the 40–400, 22–120, and >30 pg/ml found in pre-,
peri-, and post-menopausal women. Oestradiol concentrations
were not significantly altered following administration of Zol
(Figure 1A), and serum FSH concentrations remained below the
level of detection by ELISA in all mice (Supplementary Figure
S4). Removing oestrogen by OVX and administration of goserelin
caused withering of mouse uterus and a significant reduction in
uterus weight (p < 0.001); this was restored following
supplementation with premenopausal concentrations of
oestradiol but not with perimenopausal concentrations of this
hormone. Uterus appearances and weights were not altered
following administration of Zol (Supplementary Figure S1).
Oestradiol had significant effects on trabecular bone volume:
BV/TV% was higher in the trabecular bone in tibiae of mice
following exposure to premenopausal concentrations of oestradiol
compared with peri- or post-menopausal concentrations (p <
0.001); BV/TV% was also higher in trabecular bone of tibiae
exposed to perimenopausal concentrations of oestradiol compared
with pre- or post-menopausal concentrations (p < 0.001 and p <
0.01, respectively) (Figure 1B). Administration of Zol caused an
increase in trabecular BV/TV% under all concentrations of
oestradiol; however, under peri- and post-menopausal
concentrations (BV/TV = 13.97% ± 1.13% and 11.45% ± 1.99%,
respectively), Zol did not increase bone volume to levels observed
under premenopausal oestrogen conditions (BV/TV = 18.70% ±
1.48%; Figure 1B). These data suggest that oestradiol has a more
potent bone-building effect than Zol in the trabecular area of bone.
Interestingly, differences in trabecular bone volume observed in
OVX mice following supplementation with pre-, peri-, and post-
menopausal concentrations of oestradiol were not due to changes in
trabecular thickness (Figure 2A). Instead, oestradiol appeared to
directly influence trabecular number; mice supplemented with
premenopausal concentrations of oestradiol exhibited significantly
increased trabecular number compared with mice supplemented
with perimenopausal (p < 0.001) or postmenopausal concentrations
of oestradiol (p < 0.0001). In contrast, administration of Zol
increased trabecular thickness in mice supplemented with pre-
(p < 0.0001) and peri- (p < 0.001) menopausal concentrations of
oestradiol (Figure 2A) but did not alter trabecular number
(Figure 2B), suggesting that oestradiol and Zol affect bone
formation via different mechanisms. Trabecular separation was not
affected by either oestradiol or Zol (Figure 2C). Oestradiol
significantly impacted the quality of trabecular bone; trabecular
pattern factor was significantly lower under premenopausal
concentrations of oestradiol compared with peri- (p < 0.0001) or
post- (p < 0.0001) menopausal oestradiol. Interestingly, Zol
improved the quality of bone under premenopausal concentrations
of oestradiol (p < 0.0001) but had no affect on trabecular pattern
factor in trabecular bone under peri- or post-menopausal
concentrations of oestradiol (Figure 2D).
Effects on cortical bone were less pronounced; cortical thickness
was slightly, but not significantly, reduced in mice with peri- and
post-menopausal concentrations of oestradiol compared with mice
with premenopausal concentrations of oestradiol (cortical bone
thickness = 0.047 ± 0.01 mm, 0.47 ± 0.02mm, and 0.53 ± 0.02 mm,
respectively). Furthermore, Zol did not increase cortical bone
volume when administered under premenopausal oestradiol but
increased cortical volume back to control levels when administered
under peri- and post-menopausal oestradiol (cortical bone
thickness = 0.55 ± 0.02 mm, 0.57 ± 0.01 mm, and 0.55 ± 0.02
mm, respectively) (Figure 2E).
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Reduced bone volume observed under postmenopausal
concentrations of oestradiol appears to be driven by elevated bone
turnover with increased osteoclast number and activity (Figures 1C,
D) and increased activity of osteoblasts (Figure 1F). Alternatively,
increased bone volume following administration of Zol was
primarily driven by reduced osteoclast activity with only small
changes in osteoblast numbers being detected but no changes in
activity (Figures 1C–F). Interestingly, under postmenopausal
concentrations of oestradiol, representing conditions in which
adjuvant Zol exerts maximum antimetastatic effects in breast
cancer patients, administration of Zol reduced the activity of both
osteoblasts and osteoclasts (Figures 1C, D), implying that Zol may
exert increased antiresorptive effects in trabecular bone when
oestradiol is low.
Effects of Oestradiol and Zoledronic Acid
on Metastatic Outgrowth of Breast Cancer
Cells in Bone
Clinical trials have demonstrated that adjuvant Zol reduced
subsequent development of tumour relapse in bone independently
ofmenopausal status or serumoestradiol concentrations (16, 17, 19).
We therefore used avarietyof in vivomodels of bonemetastasis to see
if we could mimic this effect in mice (Figure 3). In
immunocompromised BALB/c nude mice, oestradiol had no effect
on the number of mice developing tumours in bone following i.c.
injection of humanMDA-MB-231 cells (Figure 3Bi) nor did it affect
the volume of these tumours (Figure 3Ci) . Under
immunocompromised conditions, there was a trend toward a
reduced number of mice developing bone metastasis in Zol-treated
mice, and Zol reduced the size ofmetastatic deposits under peri- and
post-menopausal concentrations of oestradiol (Figures 3Bi, Ci).
Similarly, in immunocompetent BALB/c mice, treatment with Zol
resulted in a trend toward a reduced number of bone metastasis
following i.c. injection with mouse mammary 4T1 cells; this did not
reach significance (Figure 3Bii). However, in this model, oestradiol
concentration correlatedwith increased tumourburden,with smaller
tumours detected in the bones of mice supplemented with pre- and
peri- menopausal concentrations of oestradiol compared with no-
oestradiol (p < 0.1). This increase in tumour volume was reduced
following administration of Zol (p < 0.1) (Figure 3Cii). Interestingly,
A B
C D E F
FIGURE 1 | Modelling pre-, post-, and peri-menopausal concentrations of oestrogen ± zoledronic acid in mice. Twelve-week-old immunocompetent BALB/c mice
underwent ovariectomy, and 0, 1.38, or 12.5 mg/L oestradiol was immediately supplemented via their drinking water. Three days later, five mice from each group
received subcutaneous injection of 100 mg/kg zoledronic acid or saline control. All mice received a daily injection of 40 mg/kg goserelin. All data shown are 2 weeks
following ovariectomy/oestradiol supplementation. (A) shows circulating concentrations of oestradiol in the plasma, as measured by ELISA. (B) shows the
percentage of trabecular bone volume compared with tissue volume (TV/BV%) and radiomicrographs from representative mCT images. (C, D) shows effects on
osteoblast and osteoclast activity, as measured by procollagen 1 intact N-terminal propeptide (P1NP) and tartrate-resistant acid phosphatase (TRAP) ELISA,
respectively. (E, F) show effects on numbers of osteoclasts and osteoblasts that line trabecular and cortical bone per mm, respectively. All data on histograms are
represented as mean ± SD; *p < 0.05, **p < 0.01, and ***p < 0.001.
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theopposite effectwasobserved in immunocompetentC57BL/6mice
injected with mouse mammary E0771 cells. In C57BL/6 mice,
circulating concentrations of oestradiol positively correlated with
both number and size of bone metastases. Mice supplemented with
premenopausal concentrations of oestradiol developed significantly
more bone metastases compared with mice not supplanted with
oestradiol (p < 0.01; Figure 3Biii). In this model, Zol did not reduce
bone metastases, instead, under postmenopausal concentrations of
oestradiol, mice developed significantly more bone metastases in the
Zol-treated compared with the non-Zol-treated groups (p < 0.01;
Figure 3Biii). These data suggest that Zol has the ability to reduce the
outgrowth of metastatic tumour cells in bone, but this is dependent
on additional factors including genetic background of the
host/tumour.
Effects of Oestradiol and Zoledronic Acid
on Metastatic Outgrowth of Breast
Cancer Cells in Soft Tissue
It was hypothesised that under premenopausal conditions, high
concentrations of oestradiol may cause tumour cells to move out
of the bone microenvironment, driving increased tumour
recurrence in soft tissue. Our data show a trend toward reduced
numbers of tumours in the soft tissues of mice supplemented with
peri- or post-menopausal concentrations of oestradiol compared
with mice supplemented with premenopausal concentrations of
oestradiol especially in immunocompetent BALB/c and C57BL/6
mice (Figure 4). Treatment with Zol had no effect on the number
of tumours that developed in mice but did affect tumour
volume (Figure 4B).
In immunocompromised BALB/c nude mice, oestradiol had
no effect on tumour volume, and metastatic tumour growth
outside of the skeleton was unaffected by treatment with Zol
(Figure 4Bi). However, in both immunocompetent BALB/c and
C57BL/6 models, oestradiol concentrations inversely correlated
with metastatic tumour growth outside of bone. In both of these
models, significantly larger tumour volumes were recorded in
mice supplemented with postmenopausal concentrations of
oestradiol compared with premenopausal concentrations of
oestradiol (p < 0.1; Figures 4Bii, iii). BALB/c mice treatment
with Zol had no effect on tumour growth outside of the skeleton
under premenopausal concentrations of oestradiol but
A B C
D E
FIGURE 2 | Effects of pre-, post-, and peri-menopausal concentrations of oestradiol ± zoledronic acid on trabecular and cortical bone in mouse tibiae. Twelve-
week-old immunocompetent BALB/c mice underwent ovariectomy, and 0, 1.38, or 12.5 mg/L oestradiol was immediately supplemented via their drinking water.
Three days later, 10 mice from each group received subcutaneous injection of 100 mg/kg zoledronic acid or saline control. All mice received a daily injection of 40
mg/kg goserelin. All data shown are 2 weeks following ovariectomy/oestradiol supplementation. Histograms are all mean ± SD for tibae from 10 mice per group
following mCT analysis of trabecular thickness in mm (A), trabecular number (B), trabecular separation (C), trabecular pattern factor (D), and cortical thickness (E).
*p < 0.01, **p < 0.001, and ***p < 0.0001.
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significantly reduced tumour volume under postmenopausal
concentrations of this hormone (p < 0.01; Figure 4Bii). In
C57BL/6 mice, treatment with Zol significantly increased
tumour volume outside the skeleton (p < 0.05) in mice
supplemented with premenopausal concentrations of oestradiol
but reduced tumour volume under postmenopausal
concentrations of oestradiol (p < 0.05; Figure 4Biii). These
data suggest that low circulating concentrations of oestradiol
stimulate growth of disseminated tumour cells outside of bone
and that Zol is only able to exert antitumour effects on
extraskeletal metastasis in low oestradiol conditions.






FIGURE 3 | Effects of pre-, post-, and peri-menopausal concentrations of oestradiol ± zoledronic acid on tumour growth in bone. Photographs show representative
IVIS images of tumours growing in live animals (A). Histograms show the numbers of overt metastases that form in the skeleton (B) and the bioluminescence signal in
photons per second (P/S) from Luc2-expressing tumour cells in bone (C) in BALB/c fox/- mice injected with MDA-MB-231 cells (i), BALB/c mice injected with 4T1 cells
(ii), and C57BL/6 mice injected with E0771 cells (iii) (n = 10/group). Cell lines were disseminated directly into the bloodstream of the mouse via intracardiac injection 3,
6, and 7 days after induction of pre-, peri-, or post-menopausal concentrations of oestradiol in BALB/c nude, BALB/c, and C57BL/6, respectively, and 3 days after first
injection of zoledronic acid. Zoledronic acid was administered weekly at a dose of 100 mg/kg, and all mice received daily injection of goserelin (40 mg/kg). All data on
histograms are represented as mean ± SD; *p < 0.05.
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by the adaptive immune system, as neither oestradiol nor Zol
affected extraskeletal metastasis in athymic BALB/c nude mice.
Previously published studies have indicated that antimetastatic
effects of Zol correlate with that tumour cell expression of the
transcription factor MAF (28), whereas other studies have shown
that high expression of GIPC1 and CAPG is associated with
antitumour activity of Zol in breast cancer patients (24). We
therefore investigated the expression profile of these genes in our
breast cancer models. Using Real Time QPCR, MAF was not
detected within 30 amplification cycles in bone homing, MDA-
MB-231, 4T1, or E0771 cells, indicating that this gene is not
expressed in these cell lines. In contrast, CAPG and GIPC1 are
highly expressed in the bone homing clones used for current
experiments, with no significant differences detected (Figure 5).
GIPC1 and CAPG were detected at 15.22 ± 3.12 and 21.80 ± 1.15
cycles, respectively, compared with 15.22 ± 3.12 for GAPDH in
MDA-MB-231 cells; in 4T1 cells, GAPC1, CAPG, and GAPDH
were detected at 17.14 ± 2.11, 20.34 ± 2.55, and 16.18 ± 2.33 cycles,
respectively; and in E0771 cells, GAPC1 and CAPG were detected
after 19.225 ± 3.112 and 23 ± 3.562 cycles compared with 18.21
cycles for GAPDH.
Effects of Oestradiol and Zoledronic Acid
on the Bone Microenvironment of
Tumour-Bearing Mice
Evidence from the literature suggests a strong link between bone
turnover and metastatic outgrowth in bone (25, 29–31). We
therefore investigated whether differential effects of oestradiol
and Zol on bone metastasis observed between BALB/c/BALB/c
nude and C57BL/6 mice (Figure 3) could be explained by effects
of this hormone/drug on bone turnover. As previous experiments
showed that Zol does not affect oestradiol-induced changes in
cortical bone (Figure 2E) but has profound effects on oestradiol-
induced changes in trabecular bone (Figures 1, 2), which is also
the area in which tumours form in mouse models of bone
metastasis, we focused our analysis on trabecular bone volume.
mCT analysis of trabecular bone from the tibiae of mice revealed
that administration of premenopausal concentrations of oestradiol
had similar effects on all mouse strains, resulting in BV/TV% of
20.36 ± 1.06 in BALB/c nude, 21.82 ± 0.91 in BALB/c, and 20.22 ±
2.0 in C57BL/6 (Figure 6). Reducing oestradiol had significant
effects on bone turnover, with the greatest effects observed in
BALB/c nude mice in which perimenopausal concentrations of
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FIGURE 4 | Effects of pre-, post-, and peri-menopausal concentrations of oestradiol ± zoledronic acid on soft tissue metastasis. Histograms show the numbers of
overt metastases that form outside the skeleton (A) and the bioluminescence signal in photons per second (P/S) from Luc2-expressing tumour cells outside of bone
(B) in BALB/c fox/- mice injected with MDA-MB-231 cells (i), BALB/c mice injected with 4T1 cells (ii), and C57BL/6 mice injected with E0771 cells (iii) (n = 10/group).
Cell lines were disseminated directly into the bloodstream of the mouse via intracardiac injection 3, 6, and 7-days after induction of pre-, peri-, or post-menopausal
concentrations of oestradiol in BALB/c nude, BALB/c, and C57BL/6, respectively, and 3 days after first injection of zoledronic acid. Zoledronic acid was administered
weekly at a dose of 100 mg/kg, and all mice received daily injection of goserelin (40 mg/kg). All data on histograms are represented as mean ± SD; *p < 0.05.
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oestradiol reduced trabecular bone volume to 6.38% ± 0.45%, and
this remained at a similar volume (8.08% ± 0.70%) under
postmenopausal oestradiol. Immunocompetent BALB/c and
C57BL/6 exhibited a more gradual response to changes in
oestradiol, with significant reductions in bone volume being
recorded between mice supplemented with pre- and peri-
menopausal concentrations of oestradiol (p < 0.0001 for BALB/c
and C57BL/6) and further reductions observed between mice
supplemented with peri- and pre-menopausal concentrations of
this hormone (p < 0.001 and p < 0.01 for BALB/c and C57BL/6,
respectively). Interestingly, in tumour-bearing mice,
administration of Zol only increased bone volume in C57BL/6
mice under postmenopausal concentrations of oestradiol
(Figure 6). In immunocompromised BALB/c nude and
immunocompetent BALB/c mice, reduced bone volume
observed in mice with peri- and post-menopausal
concentrations of oestradiol compared with premenopausal
concentrations of this hormone correlated with increased
activity of osteoblasts (Figures 7Ai, ii) and osteoclasts
(Figures 7Bi, ii), indicating increased bone turnover. Oestradiol
did not appear to alter activity of either osteoclasts or osteoblasts
in C57BL/6 mice on termination of this experiment
(Figures 7Aiii, Biii). Interestingly, administration of Zol
reduced osteoblast activity under pre- and peri-menopausal
concentrations of oestradiol in BALB/c nude (p < 0.001 and p <
0.01 for pre- and peri-menopausal, respectively) and BALB/c (p <
0.01 and p < 0.001 for pre- and peri-menopausal, respectively)
mice. Conversely, in C57BL/6mice, Zol reduced osteoblast activity
under peri- and post-menopausal concentrations of oestradiol
(p < 0.001 and p < 0.001, respectively; Figure 7A). Zol significantly
reduced osteoclast activity in both background strains of
immunocompetent and immunocompromised independently of
circulating concentrations of oestradiol (Figure 7B). These
differences observed in the regulation of osteoblast activity may,
in part, contribute to the opposing antitumour effects observed in
the bones of BALB/c and C57BL/6 mice following administration
of Zol (Figure 3).
DISCUSSION
The aim of the current study was to identify if oestrogen was the
driver for the differential benefits that adjuvant Zol is having in
clinical studies, with postmenopausal breast cancer patients
gaining a survival advantage from receiving adjuvant Zol, while
premenopausal women do not (16, 17). Multiple clinical trials
have demonstrated that pre-, peri-, and post-menopausal women
all benefit from reduced bone metastasis when Zol is
administered along with adjuvant standard of care. However,
in postmenopausal women, this treatment has the added benefit
of reducing soft tissue metastasis and increasing survival
compared with standard of care alone. The same advantage is
not seen in pre- or peri-menopausal women, with some studies
showing no reduction in soft tissue metastasis and the AZURE
study even suggesting reduced survival following adjuvant Zol in
this population (17). Evidence from these clinical trials suggest
that the antitumour benefits of adjuvant Zol, outside of bone, are
specifically correlated with oestradiol and/or FSH rather than
inhibin levels and are independent of tumour subtype (20). We
therefore designed the current study to specifically investigate the
effects of Zol under pre-, peri-, and post-menopausal
concentrations of oestradiol only (FSH low in all) on the
outgrowth of metastatic tumour cells, inside and outside of
bone. For this study, we selected to use triple-negative human
and mouse breast cancer cell lines to negate any direct effects of
oestradiol on the cancer cells and to allow us to account for
differences in the genetic/immunological background of the host.
We originally hypothesised that administration of Zol under
high concentrations of oestradiol may create a bone
microenvironment that is unattractive to tumour cells,
promoting their relocation from skeletal sites to soft tissue, thus
promoting increased soft tissue metastasis observed in the AZURE
trial. In order to test this, we built mouse models to mimic serum
oestradiol concentrations that are observed in pre-, post-, and
peri-menopausal women but with no associated change in serum
FSH levels (Figure 1 and Supplementary Figure S4). We found
that supplementing OVX mice with 12.5, 1.38, or 0 mg/L resulted
in serum concentrations of oestradiol that are comparable to the
40–400, 22–120, and >30 pg/ml found in pre-, peri-, and post-
menopausal women, respectively (www.urmc.rochester.edu).
Furthermore, adding a daily injection of goserelin prevented
production of FSH, thus creating models suitable for studying
menopause-specific concentrations of oestradiol. In our models,
reducing oestradiol to peri- or post-menopausal concentrations
significantly reduced bone volume through increased osteoclast
FIGURE 5 | Musculoaponeurotic fibrosarcoma (MAF), PDZ domain
containing protein GIPC1 (GIPC1), and macrophage capping protein (CAPG)
gene expression profiles in human and mouse bone homing cell lines. Bone
homing variants of MDA-MB-231, 4T1, and E0771 cells used in this project
were tested for expression of MAF, GIPC1, and CAPG, along with the
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) by
real-time QPCR. Data shown are mean ± SEM for three repeats of
experiments carried out in duplicate. ND, Not Detected.
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activity, as is also observed in women during the same
representative stages of menopause, providing evidence that our
model is representative of the human condition (32, 33). Zol has
well-characterised properties of inhibiting bone resorption via
preventing osteoclast activity and causing osteoclast apoptosis in
both mouse models and humans (34–36). Our data suggest that
the ability of Zol to reduce osteoclastic bone resorption is not
affected by oestradiol (Figures 1, 7), and in the absence of tumour,
Zol increases bone mass under pre-, peri-, and post-menopausal
concentrations of this hormone. Interestingly, despite its anti-
osteoclastic properties, administration of Zol to peri- and post-
menopausal mice did not restore bone to the same densities
observed in premenopausal mice, suggesting that the anabolic
effects of oestradiol outweigh the anti-resorptive effects of Zol in
our models and that this differential may contribute to the
movement of tumour cells from the bone microenvironment to
soft tissues in a premenopausal environment. The finding that Zol
was only able to elicit anti-resorptive effects in trabecular bone but
not cortical bone under premenopausal concentrations of
oestradiol is particularly interesting, as the trabecular region is
the area of bone that tumour cells home to and grow in mouse
models (31, 37).
Reduced bone metastasis observed in breast cancer patients
treated with adjuvant Zol was partly reproduced in our mouse
models; however, this was dependent on the background strain
of the mouse. Mice from a BALB/c background showed a trend
toward reduced bone metastasis following administration of Zol,
and this was independent of oestradiol concentrations, a
functional adaptive immune system, or tumour (human MDA-
MB-231 or mouse 4T1). Whereas mice from a C57BL/6
background developed significantly more bone metastases
following Zol under postmenopausal concentrations of
oestradiol (Figure 2). We know that not all breast cancer
patients benefit from reduced bone metastasis following
adjuvant Zol, and these data indicate that genetic background
may be an important factor in determining therapeutic benefit in
bone. Evidence from clinical studies has demonstrated that the
therapeutic benefit is not determined by oestrogen receptor or
human epidermal growth factor receptor 2 (HER2) receptor
status of the tumour (16–19). However, separate studies have
shown convincing evidence that tumour cell expression of the
transcription factor MAF strongly correlates with antimetastatic
effects of Zol (28), and combined high expression levels of GIPC1
and CAPG strongly correlate with increased likelihood of
A
B
FIGURE 6 | Effects of zoledronic acid on trabecular bone volume in mice supplemented with pre-, post-, and peri-menopausal concentrations of oestradiol following
injection of tumour cells. Radiographs show cross-sectional mCT images of trabecular bone (A). Histograms show mean ± SD percentage of trabecular bone volume
compared with tissue volume (BV/TV%) (B) in BALB/c fox/- mice injected with MDA-MB-231 cells, BALB/c mice injected with 4T1 cells, and C57BL/6 mice injected
with E0771 cells (n = 10/group). Cell lines were disseminated directly into the bloodstream of the mouse via intracardiac injection 3, 6, and 7 days after induction of
pre-, peri-, or post-menopausal concentrations of oestradiol in BALB/c nude, BALB/c, and C57BL/6, respectively, and 3 days after first injection of zoledronic acid.
Zoledronic acid was administered weekly at a dose of 100 mg/kg, and all mice received daily injection of goserelin (40 mg/kg). Statistical significance is represented
as *p < 0.05, **p < 0.01, and ***p < 0.001.
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developing distant recurrence in bone, with this genotype also
conferring increased antitumour sensitivity to adjuvant Zol (24).
However, in our mouse models, differences in antimetastatic
response to Zol do not appear to be driven by any of these
proteins, asMAF gene expression below the level of detection by
PCR in all three cell lines used and both CAPG and GIPC1 are
highly expressed in the bone homing clones used for the current
experiments (Figure 5), suggesting the importance of other, yet
to be identified, genetic determinants in this process.
Furthermore, using the MDA-MB-231 model of breast cancer
bone metastasis, we and others have previously shown that Zol
was only able to elicit an antitumour response in bone under
postmenopausal conditions (25, 29, 38). We originally
hypothesised that this was due to oestradiol-driven effects on
osteoclasts promoting increased bone turnover and stimulating
tumour growth, which could be inhibited by reduced activation
of osteoclasts (25, 29). This hypothesis initially appeared to be
supported by laboratory data showing that reducing osteoclastic
bone resorption with the fc fragment of osteoprotegrin (OPGfc)
could also inhibit bone metastasis under post- but not pre-
menopausal conditions (25). However, increasing clinical evidence
suggests that antitumour effects observed in postmenopausal
women are only seen following administration of bisphosphonates
and not seen following treatment with other osteoclast inhibitors
such as denosumab (14). In the aforementioned previously
published mouse studies, mice were rendered premenopausal by
OVX but not administered goserelin, resulting in both reduced
oestradiol and increased FSH. It is therefore possible that FSH and
oestrogen may play important roles in the antitumour effects of Zol
in bone and that these effects may not primarily be driven by
osteoclast-driven alterations to bone resorption. These theories
warrant further investigation.
Evidence from preclinical in vivo studies has shown that
supplementing mice with oestradiol enhanced spontaneous
metastasis of ER+ve cells to bone (13), suggesting that high
oestradiol may attract tumour cells to bone and may influence
whether they survive/become dormant cells in the bone
microenvironment or disseminate to other organs. Our current
study suggests that, in models of triple-negative breast cancer,
premenopausal concentrations of oestradiol are supportive of
increased tumour cell dissemination in both bone and soft tissues
especially inmice on a C57BL/6 background. Oestradiol did not affect
Ai ii iii
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FIGURE 7 | Effects of zoledronic acid on bone cell activity in mice supplemented with pre- peri- and post- menopausal concentration of oestradiol following tumour
cell injection. Histograms show osteoblast activity as measured by P1NP ELISA (A) and osteoclast activity as measured by TRAcP5 b activity (B) from the serum of
BALB/c fox/- mice (i), BALB/c (ii) and C57BL/6 (iii) mice injected with MDA-MB-231, 4T1 and E0771 cells respectively (n=10/group). Cell lines were disseminated
directly into the blood stream of the mouse via intra-cardiac injection 3, 6 and 7-days after induction of pre- peri or post-menopausal concentrations of oestradiol in
BALB/c nude, BALB/c and C57BL/6 respectively and 3 days after first injection of zoledronic acid. Zoledronic acid was administered weekly at a dose of 100ug/kg
and all mice received daily injection of goserelin (40ug/kg). All data are shown as mean +/- SD and statistical significance are represented as *P < 0.05, **P < 0.01
and ***P < 0.001.
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the numbers of tumours that developed in bones or soft tissues of
immunocompromised BALB/c nude mice and only partially affected
thenumberof tumour cells that developed in the soft tissuesofBALB/c
mice. As BALB/c nude mice have no T cells and reduced innate
immunity and immunocompetent BALB/c mice elicit less of an
immune response when faced with challenge compared with C57BL/
6 mice (39), our data suggest that oestrogen effects on antitumour
immune response may play important roles in how this hormone
regulates tumour cell dissemination and metastatic outgrowth. In
agreement with a potential role for the immune response in
regulating soft tissue metastases, reducing oestradiol concentrations
to those observed in postmenopausal women resulted in significant
increases in tumour volume in the soft tissues of immunocompetent
BALB/c andC57BL/6mice but did not affect growth of tumours in the
soft tissues of immunocompromised mice (Figure 3). Immune
response also appeared to be important in the antitumour effects of
Zol outside of bone. Zol did not exert antitumour effects in the soft
tissues of immunocompromised mice but significantly reduced
tumour volume under postmenopausal concentrations of oestradiol
in immunocompetent mice (Figure 3). Importantly, both
immunocompetent models mimicked human clinical trials well,
with 4T1 cells in BALB/c mice showing no benefit following
administration of Zol and E0771 cells in C57BL/6 mice showing
reduced benefit following Zol under premenopausal oestradiol as in
theABCSG-12andAZUREtrials, respectively (16–18).Bothoestradiol
and Zol have well-documented effects on immune cell regulation.
Oestrogen has immunogenic properties, influencing the activity of
dendritic cells, macrophages, mast cells, neutrophils, natural killer
(NK) cells, B cells,CD4+Tcells, and regulatoryTcells (Tregs) (40–42),
as well as increasing the protein expression of programmed death
ligand 1 (PD-L1) on tumour cells (43). Whereas Zol influences
macrophage polarisation in the tumour microenvironment, gdT-cell
activation, NK cell activity, Treg activation and infiltration, PD-L1
expression, and T-cell function (44–47). The effects of oestrogen and
Zol on the immune system are both profound and often opposing
[reviewed in (15)], and it is possible that oestrogen-driven effects on
immunomodulation contribute to the differential effects of Zol
observed in pre- and post-menopausal women; this hypothesis
warrants further investigation.
Taken together, our new data suggest that oestradiol
significantly contributes to altered antitumour effects of Zol
observed between pre- and post-menopausal women possibly
through differing effects on immune cells. However, other genetic
and microenvironmental factors including immune regulation
are also likely to contribute to the ability of Zol to exert
antitumour activity in individual patients.
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